GT Biopharma, Inc. (GTBP) › Net IncomeGT Biopharma, Inc. (GTBP) — Net IncomeAnnual figures by period end, from SEC filings.2010-12-31: -$3.00M2011-12-31: -$3.70M2012-12-31: -$5.17M2013-12-31: -$501.0K2014-12-31: -$23.49M2015-12-31: -$21.46M2016-12-31: $9.77M2017-12-31: -$144.17M2018-12-31: -$259.19M2019-12-31: -$38.65M2020-12-31: -$28.30M2021-12-31: -$58.01M2022-12-31: -$20.88M2023-12-31: -$7.60M2024-12-31: -$13.16M2025-12-31: -$28.35M-$28.35M2010-12-31Net Income (USD)2025-12-31Period endedNet IncomeChange YoYSource filing2025-12-31-$28.35M—2026-03-02From 2025-01-012024-12-31-$13.16M—2026-03-02From 2024-01-012023-12-31-$7.60M—2025-02-21From 2023-01-012022-12-31-$20.88M—2024-03-26From 2022-01-012021-12-31-$58.01M—2023-03-30From 2021-01-012020-12-31-$28.30M—2022-03-28From 2020-01-012019-12-31-$38.65M—2021-04-16From 2019-01-012018-12-31-$259.19M—2020-03-27From 2018-01-012017-12-31-$144.17M-1576.0%2019-03-29From 2017-01-012016-12-31$9.77M—2018-03-01From 2016-01-012015-12-31-$21.46M—2018-02-28From 2015-01-012014-12-31-$23.49M—2018-02-28From 2014-01-012013-12-31-$501.0K—2015-03-31From 2013-01-012012-12-31-$5.17M—2015-01-08From 2012-01-012011-12-31-$3.70M—2014-11-18From 2011-01-012010-12-31-$3.00M—2012-04-16From 2010-01-01Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)